Ettinger A B, Jandorf L, Berdia A, Andriola M R, Krupp L B, Weisbrot D M
Department of Neurology, State University of New York at Stony Brook 11794-8121, USA.
Epilepsia. 1996 May;37(5):503-5. doi: 10.1111/j.1528-1157.1996.tb00599.x.
We prospectively investigated drug-induced headaches (HA) among 60 epileptic patients receiving felbamate (FBM). Twenty patients (33%) experienced HA. HA was pounding in 11 (55%), steady in 9 (45%), moderate or severe in 19 (95%), occurred at least once a week in all patients, and was relieved by nonnarcotic analgesics in 14 (70%). Mean duration on FBM before HA onset was 19 days. HA occurred with higher FBM doses and was relieved in 8 of 13 patients (62%) with FBM dose reduction. FBM was discontinued in most cases because of risks of anemia or hepatitis; not because of HA. Other side effects included insomnia (25%), gastrointestinal symptoms (27%), and agitation or restlessness (23%). HA is a common dose-related complication of FBM, occurs early after initiation of FBM treatment, and is relieved by dose reduction.
我们对60例接受非氨酯（FBM）治疗的癫痫患者进行了前瞻性药物性头痛（HA）调查。20例患者（33%）出现HA。11例（55%）为搏动性头痛，9例（45%）为持续性头痛，19例（95%）为中度或重度头痛，所有患者每周至少发作一次，14例（70%）患者服用非麻醉性镇痛药后头痛缓解。HA发作前服用FBM的平均时长为19天。FBM剂量越高，HA发生率越高，13例患者中有8例（62%）在降低FBM剂量后头痛缓解。大多数情况下停用FBM是因为有贫血或肝炎风险，而非HA。其他副作用包括失眠（25%）、胃肠道症状（27%）以及激动或烦躁不安（23%）。HA是FBM常见的剂量相关并发症，在开始FBM治疗后早期出现，降低剂量可缓解。
